Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX208 Plus Cetuximab in BRAF V600E Mutated mCRC
NCT04984369Phase 2Unknown
- Sponsor
- Henlius
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HLX208 in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Henlius. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
HLX208
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04984369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984369.